Article

Wait time to nephrectomy does not affect recurrence

Waiting time to nephrectomy is not a predictor of the recurrence of renal cell carcinoma.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
Rethinking First-Line Treatments: Will BCG Continue to Be the Standard in NMIBC?
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
In the Pipeline: Novel Treatment Delivery Methods for NMIBC
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Investigators assess ctDNA’s role in NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: Implementing mitomycin for LG-IR-NMIBC in clinical practice
Urology Times Mitomycin RX Review Square Thumb
RX Review: TURBT vs chemoablation for low-grade, intermediate-risk NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: A paradigm shift for low-grade, intermediate-risk NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: How mitomycin for intravesical solution works in treating LG-IR-NMIBC
Urology Times Mitomycin RX Review Square Thumb
RX Review: Redefining treatment for LG-IR-NMIBC
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Vignesh Packiam, MD, on the MOA, dosing of detalimogene voraplasmid
Stethoscope and doctor sitting with laptop stress headache about work in hospital | Image Credit: © joyfotoliakid - stock.adobe.com
Understanding pediatric urologist burnout
Related Content
Regulatory recap: FDA approvals in urology from the first half of 2025
July 4th 2025

Regulatory recap: FDA approvals in urology from the first half of 2025

Hannah Clarke
Take a look through all the regulatory milestones in urology from the first half of the 2025.
Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD
June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD
Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.
FDA logo
July 3rd 2025

FDA news recap in urology for Q2 2025

Hannah Clarke Benjamin P. Saylor Jason M. Broderick
Here’s a look back at notable news between April and June 2025.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC
July 2nd 2025

Enrollment begins in phase 2 trial of opaganib plus darolutamide in mCRPC

Hannah Clarke
The study will utilize the companion lipid biomarker test, PCPro, to identify patients who may benefit from the addition of opaganib to darolutamide.
Study launches of first-in-class aromatase inhibitor for male infertility
July 1st 2025

Study launches of first-in-class aromatase inhibitor for male infertility

Hannah Clarke
The trial is evaluating the efficacy of leflutrozole in improving testicular function and promoting spermatogenesis.
© 2025 MJH Life Sciences

All rights reserved.